Thrombin mediates fibrin polymerization and is known to be involved in acute and chronic inflammatory processes in vivo. Flick et al. have used various genetically engineered mouse models to study ...
In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...
Fibrinolytic therapy, also known as thrombolytic therapy, is used to lyse acute blood clots by activating plasminogen, resulting in the formation of plasmin, which cleaves the fibrin cross-links ...
GlobalData on MSN10d
Genentech wins FDA approval for second stroke treatmentGenentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback